Quest / Hologic Pact Squeezes Qiagen – Barron’s

Quest / Hologic Pact Squeezes Qiagen
Barron’s
Qiagen (ticker: QGEN) expects the impact on their digene human papillomavirus (HPV) test to be minimal and has reconfirmed its 2013 guidance, while assuming an impact of less than 2% on 2014 net sales. Importantly, we (and we believe consensus) have 

and more »

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *